Hemispherx BioPharma, Inc Share Price Nyse
Equities
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 113K 9.05M | Sales 2025 * | 1.78M 142M | Capitalization | 21.79M 1.74B |
---|---|---|---|---|---|
Net income 2024 * | -24M -1.92B | Net income 2025 * | -25M -2B | EV / Sales 2024 * | 192 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 12.2 x |
P/E ratio 2024 * |
-0.89
x | P/E ratio 2025 * |
-0.96
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91% |
Latest transcript on Hemispherx BioPharma, Inc
Managers | Title | Age | Since |
---|---|---|---|
Thomas Equels
CEO | Chief Executive Officer | 71 | 16/11/08 |
Robert Dickey
DFI | Director of Finance/CFO | 68 | 03/04/22 |
Chief Tech/Sci/R&D Officer | - | 31/05/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nancy K. Bryan
BRD | Director/Board Member | 66 | 27/03/23 |
William Mitchell
CHM | Chairman | 89 | 30/06/98 |
Thomas Equels
CEO | Chief Executive Officer | 71 | 16/11/08 |
1st Jan change | Capi. | |
---|---|---|
+3.81% | 108B | |
+11.14% | 104B | |
+1.28% | 22.33B | |
-12.86% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.63% | 17.64B | |
+3.77% | 14.05B | |
+37.32% | 12.51B |